<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="NMR or Xâ€�ray crystallography, or even the highâ€�throughput networkâ€�based inhibitor" exact="screening" post="or direct ligandâ€�based study (Jin et al., 2020; Vuong"/>
 <result pre="et al., 2020; Vuong et al., 2020). While ligandâ€�based inhibitors" exact="screening" post="leads to the determination of complexed crystal structure of"/>
 <result pre="this approach aids in the structureâ€�assisted drug design and highâ€�throughput" exact="screening" post="for potential inhibitors (Jin et al., 2020). The inhibitors"/>
 <result pre="as chloroquine and formoterol have been investigated recently for the" exact="treatment" post="of COVIDâ€�19 (Rimanshee, Amit, Vishal, &amp;amp; Mukesh, 2020; Wu"/>
 <result pre="druggable target for the development of potent therapy against SARSâ€�CoVâ€�2" exact="infection" post="(Kandeel, Ibrahim, Fayez, &amp;amp; Alâ€�Nazawi, 2020; Lung et al.,"/>
 <result pre="2017). Furthermore, Remdesivir showed high considerable efficacy in controlling SARSâ€�CoVâ€�2" exact="infection" post="in a recent in vitro study (Wang et al.,"/>
 <result pre="inhibitors to SARSâ€�CoVâ€�2 S protein provide promising avenues for SARSâ€�CoVâ€�2" exact="treatment" post="by blocking the S protein interaction with ACE2 and"/>
 <result pre="information for finding antigens with improved sensitivity for SARSâ€�CoVâ€�2 serological" exact="detection" post="and vaccine development. Envelope protein E protein of coronavirus"/>
 <result pre="have facilitated a more favorable personâ€�toâ€�person transmission of the SARSâ€�CoVâ€�2" exact="infection" post="than the SARSâ€�CoV (Hoffmann et al., 2020). ACE2 can"/>
 <result pre="thus act as a unique adhesion protein molecule for SARSâ€�CoVâ€�2" exact="infection" post="and be a promising drug target for the prevention"/>
 <result pre="was carried out recently and suggested to use for the" exact="treatment" post="of COVIDâ€�19 (Khan et al., 2017; Zhang, Penninger, et"/>
 <result pre="of all organs, the lungs are more susceptible to SARSâ€�CoV" exact="infection" post="(Hamming et al., 2004). This phenomenon strengthens the possibility"/>
 <result pre="TMPRSS2â€�expressing in VeroE6 cell line is highly susceptible to SARSâ€�CoVâ€�2" exact="infection" post="displaying the critical role of TMPRSS2 in the pathogenesis"/>
 <result pre="might be repurposed as a TMPRSS2 inhibitor for preventing SARSâ€�CoVâ€�2" exact="infection" post="as well (Hoffmann et al., 2020). 3.2.3 Targets on"/>
 <result pre="for SARS (NSPS), 2004). Recent epidemiological studies showed that SARSâ€�CoVâ€�2" exact="infection" post="in children is less frequent and lethal compared to"/>
 <result pre="a possible way to find a remedy against SARSâ€�CoVâ€�2. Arabinoxylan" exact="treatment" post="resulted in the upregulation of NK cells against neuroblastoma"/>
 <result pre="(PÃ©rezâ€�MartÃ­nez et al., 2015). Arabinoxylan, therefore, possesses potentiality for the" exact="treatment" post="of COVIDâ€�19 patients; however, clinical trials are needed to"/>
 <result pre="disease prognosis and also to enhance autophagocytosis as a possible" exact="treatment" post="corridor. 4 POTENTIAL THERAPEUTICS Many potential therapeutics are currently"/>
 <result pre="different stages of clinical trials, to find out an effective" exact="treatment" post="for COVIDâ€�19, including drugs that have already proven effective"/>
 <result pre="strategy to develop urgent therapeutics. More than one drug and" exact="treatment" post="strategy might prove its worth, and different strategies might"/>
 <result pre="its worth, and different strategies might work effectively at different" exact="infection" post="stages and risk groups. The big challenge will be"/>
 <result pre="little patients in the trial. Besides, developing new drugs or" exact="testing" post="procedures may take several years to develop. That is"/>
 <result pre="2020). A recent clinical trial (ChiCTR2000029308), however, showed that lopinavirâ€&quot;ritonavir" exact="treatment" post="caused no benefit to hospitalized patients with severe COVIDâ€�19"/>
 <result pre="participants is underway with Favipiravir combined with Tocilizumab for the" exact="treatment" post="of COVIDâ€�19 at Peking University First Hospital (Table 3)."/>
 <result pre="(2020) studied the effects of Favipiravir versus Lopinavir/ritonavir for the" exact="treatment" post="of COVIDâ€�19. There were two arms (Favipiravir + Interferonâ€�Î±"/>
 <result pre="in reducing the time to recovery with lower respiratory tract" exact="infection" post="(Beigel et al., 2020). Recently, the FDA approved the"/>
 <result pre="to study the efficacy of Remdesivir and Ribavirin for the" exact="treatment" post="of SARSâ€�CoVâ€�2 as alone or in combination with other"/>
 <result pre="needs further clinical trials to study the effectiveness against SARSâ€�CoVâ€�2" exact="infection" post="(Russell, Millar, &amp;amp; Baillie, 2020). Another potential option for"/>
 <result pre="the potential role of Siltuximab in treating patients with SARSâ€�CoVâ€�2" exact="infection" post="(Gritti et al., 2020). Furthermore, an observational caseâ€&quot;control study"/>
 <result pre="A clinical trial is undergoing to test whether an antiâ€�IL6" exact="treatment" post="can be effective in reducing the SARSâ€�CoVâ€�2â€�induced cytokine storm"/>
 <result pre="protein 1 â€ 1 Programmed deathâ€�1 (PDâ€�1) blocking antibody +standard" exact="treatment" post="â€ 2 Thymosin + standard treatment Phase 2 Southeast"/>
 <result pre="(PDâ€�1) blocking antibody +standard treatment â€ 2 Thymosin + standard" exact="treatment" post="Phase 2 Southeast University, China NCT04268537 Prostaglandins Naproxen Phase"/>
 <result pre="COVIDâ€�19. A vaccine can be either prophylactic, which prevents future" exact="infection" post="or therapeutic, which is used to treat diseases such"/>
 <result pre="a foundation and a template for developing vaccines against MERSâ€�CoV" exact="infection" post="(Jiang, Lu, &amp;amp; Du, 2013). However, only one MERSâ€�CoV"/>
 <result pre="an immune response in the body, which might prevent subsequent" exact="infection" post="of SARSâ€�CoVâ€�2 (Lane, 2020). The Phase 1 trial initiated"/>
 <result pre="trial yet, and no vaccines are available to prevent SARSâ€�CoVâ€�2" exact="infection" post="(Amanat &amp;amp; Krammer, 2020; Chen, Zhang, et al., 2020b)."/>
 <result pre="plasma or sera) of people who have recuperated from SARSâ€�CoVâ€�2" exact="infection" post="are used to enhance the immunity of newly infected"/>
 <result pre="on the feasibility and effectiveness of plasma therapy. Another possible" exact="treatment" post="option is monoclonal antibody therapy. Bevacizumab, a humanized monoclonal"/>
 <result pre="on the potential drug targets of therapeutic promise against SARSâ€�CoVâ€�2" exact="infection" post="and highlighted the application of the drug repurposing approach."/>
 <result pre="A. C., &amp;amp; Lane, H. C. (2020). Remdesivir for the" exact="treatment" post="of Covidâ€�19â€&quot;Preliminary report. The New England Journal of Medicine."/>
 <result pre="J., Shu, D., Xia, J., &amp;amp; Liu, L. (2020). Experimental" exact="treatment" post="with Favipiravir for COVIDâ€�19: An openâ€�label control study. Engineering."/>
 <result pre="(2015). Treatment with Lopinavir/ritonavir or interferonâ€�Î²1b improves outcome of MERSâ€�CoV" exact="infection" post="in a nonhuman primate model of common marmoset. The"/>
 <result pre="Cellular immune responses to severe acute respiratory syndrome coronavirus (SARSâ€�CoV)" exact="infection" post="in senescent BALB/c mice: CD4+ T cells are important"/>
 <result pre="M., &amp;amp; Raoult, D. (2020). Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVIDâ€�19: Results of an openâ€�label nonâ€�randomized clinical trial."/>
 <result pre="S. A., Yan, Y., &amp;amp; Zhu, Y. (2020). Novel coronavirus" exact="treatment" post="with ribavirin: Groundwork for an evaluation concerning COVIDâ€�19. Journal"/>
 <result pre="of the index patient who caused tertiary transmission of COVIDâ€�19" exact="infection" post="in Korea: The application of Lopinavir/ritonavir for the treatment"/>
 <result pre="COVIDâ€�19 infection in Korea: The application of Lopinavir/ritonavir for the" exact="treatment" post="of COVIDâ€�19 infected pneumonia monitored by quantitative RTâ€�PCR. Journal"/>
 <result pre="M., Saito, S., Takayama, I., &amp;amp; Takeda, M. (2020). Enhanced" exact="isolation" post="of SARSâ€�CoVâ€�2 by TMPRSS2â€�expressing cells. Proceedings of the National"/>
 <result pre="(2020). Hydroxychloroquine or chloroquine with or without a macrolide for" exact="treatment" post="of COVIDâ€�19: A multinational registry analysis. Lancet. 10.1016/s0140-6736(20)31180-6 Molina,"/>
 <result pre="R. (2020). Learning from the past: Possible urgent prevention and" exact="treatment" post="options for severe acute respiratory infections caused by 2019â€�nCoV."/>
 <result pre="Baillie, J. K. (2020). Clinical evidence does not support corticosteroid" exact="treatment" post="for 2019â€�nCoV lung injury. Lancet, 395(10223), 473â€&quot;475. 10.1016/s0140-6736(20)30317-232043983 Sarma,"/>
 <result pre="&amp;amp; Munshi, N. C. (2016). Review of siltuximab in the" exact="treatment" post="of multicentric Castleman's disease. Therapeutic Advances in Hematology, 7(6),"/>
 <result pre="Phosphoramidate Prodrug of a Pyrrolo[2,1â€�f][triazinâ€�4â€�amino] adenine Câ€�nucleoside (GSâ€�5734) for the" exact="treatment" post="of Ebola and emerging viruses. Journal of Medicinal Chemistry,"/>
 <result pre="B., &amp;amp; Stanton, L. W. (2004). Inhibition of SARS coronavirus" exact="infection" post="in vitro with clinically approved antiviral drugs. Emerging Infectious"/>
 <result pre="Teixeira da Silva, J. A. (2020). Convalescent plasma: A possible" exact="treatment" post="of COVIDâ€�19 in India. Medical Journal, Armed Forces India,"/>
 <result pre="&amp;amp; Liu, L. (2004). Efficacy and safety of arbidol in" exact="treatment" post="of naturally acquired influenza. Zhongguo Yi Xue Ke Xue"/>
 <result pre="and projection of optimized dosing Design of Hydroxychloroquine for the" exact="treatment" post="of severe acute respiratory syndrome coronavirus 2 (SARSâ€�CoVâ€�2). Clinical"/>
</results>
